Antiarrhythmic efficacy, pharmacokinetics and clinical safety of tocainide in convalescent myocardial infarction patients

The antiarrhythmic efficacy and pharmacokinetics of tocainide, an oral analog of lidocaine, was evaluated in 18 hospitalized convalescing myocardial infarction patients. Holter ECG tapes were recorded daily during two-day placebo therapy preceding and succeeding two days of tocainide treatment. Left ventricular function was characterized from prior or subsequent arteriographic studies (ten cases) or from radionuclide scanning (eight cases). Tocainide dosage was 17.7 ± 4.9 SD mg/kg/day. Plasma half-time of elimination was 19.1 ± 6.8 hours (r = 0.9). Tocainide had no significant effect on heart rate, pulse rate, or QT(c) intervals and did not worsen chronic heart failure, even in patients with ejection fraction <30 percent. In seven of 18 patients, tocainide significantly reduced ventricular premature beat (VPB) frequency as compared to predrug and postdrug placebo periods. Drug responders averaged a 200 to 545 percent reduction in VPB frequency at tocainide blood levels of >3.5 μg/ml.